about
miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cellsGuidelines for the use and interpretation of assays for monitoring autophagyVoltage-gated potassium channel EAG2 controls mitotic entry and tumor growth in medulloblastoma via regulating cell volume dynamicsDrugging MYCN through an allosteric transition in Aurora kinase ACombined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable diseaseA pharmacological map of the PI3-K family defines a role for p110alpha in insulin signalingAkt and autophagy cooperate to promote survival of drug-resistant gliomaAn improved monomeric infrared fluorescent protein for neuronal and tumour brain imagingShared epigenetic mechanisms in human and mouse gliomas inactivate expression of the growth suppressor SLC5A8Subgroup-specific alternative splicing in medulloblastomaSubgroup-specific structural variation across 1,000 medulloblastoma genomesInvolvement of RhoA, ROCK I and myosin II in inverted orientation of epithelial polarityInhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumorsTh-MYCN mice with caspase-8 deficiency develop advanced neuroblastoma with bone marrow metastasis.IKK/NF-κB signaling contributes to glioblastoma stem cell maintenance.The prenatal origins of cancerIntratumoral therapy of glioblastoma multiforme using genetically engineered transferrin for drug delivery.Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma.Genetics of brain tumors.Radiation dose estimation using preclinical imaging with 124I-metaiodobenzylguanidine (MIBG) PET.Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma.Epigenomic alterations define lethal CIMP-positive ependymomas of infancyPhysiological levels of normal tRNA(CAGGln) can effect partial suppression of amber mutations in the yeast Saccharomyces cerevisiae.Mutational analysis reveals the origin and therapy-driven evolution of recurrent gliomaCell lines from MYCN transgenic murine tumours reflect the molecular and biological characteristics of human neuroblastoma.miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma.Cyclic GMP-dependent protein kinase II inhibits cell proliferation, Sox9 expression and Akt phosphorylation in human glioma cell lines.Expression quantitative trait loci and receptor pharmacology implicate Arg1 and the GABA-A receptor as therapeutic targets in neuroblastoma.Glial progenitors as targets for transformation in glioma.Principles and current strategies for targeting autophagy for cancer treatment.WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastomaNeural stem cell biology may be well suited for improving brain tumor therapies.The genetics of splicing in neuroblastoma.Radiotherapy followed by aurora kinase inhibition targets tumor-propagating cells in human glioblastomaCooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms.Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems.Can mouse models for brain tumors inform treatment in pediatric patients?Clonal selection drives genetic divergence of metastatic medulloblastoma.Asymmetry-defective oligodendrocyte progenitors are glioma precursorsSpinal Myxopapillary Ependymomas Demonstrate a Warburg Phenotype.
P50
Q21245271-20213C7E-9109-4122-A269-D7A733483695Q21996341-75A76338-5724-41BF-A75A-9AF39721FF3EQ24294672-B9D85FF1-BC78-44C0-AB48-A240A89BF765Q24303381-9D705C09-898E-4F4E-A2D3-DD4C83495656Q24310764-C21A04CF-A1D7-4523-83FC-55A507B34472Q24599676-2BEE4855-CAC6-44F6-972A-EE1197AA150CQ24629677-7F2833EC-33AC-4C2A-ABFB-295839D4E0E1Q27683806-42F1B2A7-9247-40EB-87FD-4794A518487FQ28248239-45C66C69-1AA7-4B13-B14D-1ED787A373FCQ28260516-D752DC8A-CEBA-4347-AD03-2CE685B3C31FQ28271811-330C8C21-4CF4-4C9F-BD14-267D5F84746CQ28385568-CC28EA07-6304-447D-958A-F59E43B3D41EQ28817295-97946A72-0EAE-434D-AC73-C7EB40628689Q30541198-C58A3154-CB0B-4807-9B05-F851F2B931C2Q33276239-C6AC7610-7C83-401F-8F6C-E35BE1F4AC5CQ33697463-1EF79659-D8CE-4AE2-82EC-406A7D9299FCQ33945802-6F31A24E-5F56-4ADE-8678-AA7B75CEBCB8Q34066263-F257E4C6-584A-4B12-94A3-C70ACF176FD9Q34098694-11C62BA9-37A6-4D77-8247-3E02F175AE5EQ34117552-0A5F1752-E51B-42FF-8D03-D44C8F133225Q34132926-43F154E1-3F8D-4F3E-A8D1-A1FF14E2AAE5Q34240198-64455CAE-E073-4EB7-9D4C-C4349ABB61C8Q34365885-85F112E9-E2B6-4725-9C53-27644F35F0C3Q34391844-CB013BD1-5A0E-45E8-B9D7-8614C7626A51Q34398691-5532CC82-A4EA-4353-A610-84F1B70EBD5FQ34482630-0E7B2DFA-2970-4C47-939C-A9D8E6A2922AQ34539833-CD476465-029F-4979-9DA8-E05BB37D9043Q34609220-FDA10778-C690-4314-B463-C5F77E252439Q34735661-FFAE80BD-9BCA-436E-B330-8AF2E007B20AQ34787732-6758AD0D-8E01-4424-AB05-933913AC5C61Q34979270-001B56C6-2D74-462F-8FBF-9B5793F7EDE4Q35210474-2DAB36CE-BFC8-4EDC-AACB-DE1D501290B1Q35328703-2B96AD7A-111F-46E1-B375-72B50D1D1D68Q35529926-CCE080D9-EC7F-4823-88CD-7B81B2A8D026Q35627829-1B8D26FE-C325-43B9-855C-AF6C548EB028Q35637861-5673E88E-616B-4365-B2B9-D79B5609FB73Q35646323-D385C81B-730B-4EBC-A06A-1E95CA01C7AFQ35784926-26B4823B-986D-43B3-A187-6EE7A8F9484CQ35814886-0DB31460-3B1F-45C5-9EE7-EEDD06CBED1BQ35958168-F03DD1C3-A8B6-4D35-AFFA-C17087DA6F6B
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
William A Weiss
@ast
William A Weiss
@en
William A Weiss
@es
William A Weiss
@sl
type
label
William A Weiss
@ast
William A Weiss
@en
William A Weiss
@es
William A Weiss
@sl
prefLabel
William A Weiss
@ast
William A Weiss
@en
William A Weiss
@es
William A Weiss
@sl
P106
P21
P31
P496
0000-0003-2230-9132